Home > Products > Antibodies > Biosimilars

Research Grade Etokimab (HF543016)

Price(USD): $
Spec:
  • 100ug
  • 1mg
Number:
Contact us
  • Overview
  • Images
  • References
  • Datasheet
Overview
Catalog No.HF543016
DescriptionANB020, now called etokimab, is currently in phase 2a testing in eczema, which is also known as atopic dermatitis. Scientists from the Medical Research Council Human Immunology Unit at the University of Oxford released data from 12 patients showing that 83% who were treated with etokimab reported a reduction in disease severity after 29 days. Etokimab, an anti-IL-33 biologic, has previously demonstrated a good safety profile and favorable pharmacodynamic properties in many clinical studies. Etokimab is designed to block interleukin-33 (IL-33), an immune-signaling molecule. In peanut allergy, the body overreacts to peanuts as IL-33 activates an antibody called immunoglobin E. These antibodies cause allergic response such as mouth itchiness, hives, breathing difficulties and potentially fatal anaphylactic shock.
Species reactivityHuman
ApplicationsResearch Grade Biosimilar
Host speciesHumanized
IsotypeIgG1-kappa
Expression systemMammalian Cells
SpeciesHuman
ClonalityMonoclonal
TargetNF-HEV, IL-1F11, C9orf26, IL-33, Interleukin-1 family member 11, IL33, Nuclear factor from high endothelial venules, NFHEV, Interleukin-33, IL1F11
Concentration1 mg/ml
Endotoxin levelPlease contact with the lab for this information.
Purity>95% as determined by SDS-PAGE.
PurificationProtein A/G purified from cell culture supernatant.
AccessionO95760
FormLiquid
Storage buffer0.01M PBS, pH 7.4.
Stability and StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternate NamesANB020, CAS: 2022981-44-6,IL33
NoteFor research use only. Not suitable for clinical or therapeutic use.
Images
  • Bioactivity

    SEC-HPLC detection for Research Grade Etokimab.

References

Recommendation